US FDA approves Lilly's Mounjaro to reduce cardiovascular risk

The FDA has approved Eli Lilly's drug Mounjaro (tirzepatide) to reduce cardiovascular risk in adults with type 2 diabetes. This approval marks a significant expansion of Mounjaro's use, which was previously approved for weight management and type 2 diabetes treatment. The approval is based on clinical trial data showing Mounjaro's effectiveness in reducing major cardiovascular events such as heart attacks and strokes. The approval is a major win for Lilly, positioning Mounjaro as a strong competitor in the diabetes and cardiovascular markets.

Bloomberg.com and Reuters both confirm the FDA approval. The Harvard Health article notes that Mounjaro may also lower the risk of infections, adding to its potential benefits. Fierce Pharma notes that the approval puts pressure on Novo Nordisk, a key competitor. However, the full impact of this approval on patient outcomes and market dynamics is not yet clear.

The FDA approval is specific to adults with type 2 diabetes, and the drug's effectiveness in other populations remains uncertain. Additionally, the long-term effects and potential side effects of Mounjaro are still under investigation.